Recombinant proteins in plants

Rech, E. L.; Vianna, Giovanni R.; Murad, André M.; Cunha, Nicolau Brito da; Lacorte, Cristiano; Araújo, Ana Cláudia Guerra; Brígido, Marcelo M.; Michael, Waters; Fontes, Aparecida Maria; O’Keefe, Barry; Simpson, Andrew; Otavia, Caballero

doi:10.1186/1753-6561-8-s4-o1

Cited by 12 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Production of recombinant protein from plant is believed to be a desired method for large-scale protein production considering factors including scalability, cost efficiency, and safety [134]. Growing transiently expressed or stable transgenic plants followed by protein extraction from leaf tissue allows the production of scFv molecules [4,135,136]. Besides the host-based expression systems, cell-free protein synthesis system allows high-throughput protein library generation due to the efficiency and flexibility this approach offers [137,138], and the expression of scFv molecules can be achieved without the time-consuming steps of expression vector generation and transformation.…”

Section: Strategies To Improve Bispecific Antibody Production and mentioning

confidence: 99%

Design and Production of Bispecific Antibodies

et al. 2019

View full text Add to dashboard Cite

With the current biotherapeutic market dominated by antibody molecules, bispecific antibodies represent a key component of the next-generation of antibody therapy. Bispecific antibodies can target two different antigens at the same time, such as simultaneously binding tumor cell receptors and recruiting cytotoxic immune cells. Structural diversity has been fast-growing in the bispecific antibody field, creating a plethora of novel bispecific antibody scaffolds, which provide great functional variety. Two common formats of bispecific antibodies on the market are the single-chain variable fragment (scFv)-based (no Fc fragment) antibody and the full-length IgG-like asymmetric antibody. Unlike the conventional monoclonal antibodies, great production challenges with respect to the quantity, quality, and stability of bispecific antibodies have hampered their wider clinical application and acceptance. In this review, we focus on these two major bispecific types and describe recent advances in the design, production, and quality of these molecules, which will enable this important class of biologics to reach their therapeutic potential.

show abstract

Section: Strategies To Improve Bispecific Antibody Production and mentioning

confidence: 99%

Design and Production of Bispecific Antibodies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In soybean seeds, the protein storage vacuoles (PSVs) are involved in the accumulation of ˜70% of all seed proteins (Shimada et al ., 2018 ; Tan et al ., 2019 ;) making them ideal for the accumulation of recombinant proteins (Cunha et al ., 2011a , b , 2013 , 2014a , b , 2019 , 2020 ; Jolliffe et al ., 2005 ; Rech et al ., 2014 ; Tan et al ., 2019 ; Vianna et al ., 2011a , b ; Wakasa and Takaiwa, 2013 ). Multiple recombinant proteins have therefore been expressed in soybean PSVs, including proinsulin (Cunha et al ., 2010 ), human growth hormone (Cunha et al ., 2011a ), coagulation factor IX (Cunha et al ., 2011b , 2014b ), cyanovirin‐N (O’Keefe et al., 2015 ), antibodies (Vianna et al ., 2011a , b ) and tumour antigens (Rech et al ., 2014 ). The proteins remained stable and active after 7 years of seed storage at room temperature (Cunha et al ., 2011a , b ; O’Keefe et al., 2015 ; Rech et al ., 2014 ; Vianna et al ., 2011a ).…”

Section: Molecular Farming As a Strategy To Address Established Pandemic Diseasesmentioning

confidence: 99%

“…Multiple recombinant proteins have therefore been expressed in soybean PSVs, including proinsulin (Cunha et al ., 2010 ), human growth hormone (Cunha et al ., 2011a ), coagulation factor IX (Cunha et al ., 2011b , 2014b ), cyanovirin‐N (O’Keefe et al., 2015 ), antibodies (Vianna et al ., 2011a , b ) and tumour antigens (Rech et al ., 2014 ). The proteins remained stable and active after 7 years of seed storage at room temperature (Cunha et al ., 2011a , b ; O’Keefe et al., 2015 ; Rech et al ., 2014 ; Vianna et al ., 2011a ). Cyanovirin‐N was expressed in soybean using the β‐conglycinin promoter to restrict expression to the seeds and a signal peptide to target the PSVs, resulting in the detection of the protein specifically in the seeds 4 weeks after pollination, with peak expression after 8 weeks (O’Keefe et al., 2015 ).…”

Section: Molecular Farming As a Strategy To Address Established Pandemic Diseasesmentioning

confidence: 99%

Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases

Lobato-Gómez

Huang

Alvarez

et al. 2021

Plant Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nowadays, three main strategies are employed to produce recombinant proteins: cell cultures, plant tissue-based systems, and construction of transgenic plants. The transformation methodology includes using bacterial (agroinfection) or viral infection or direct approaches such as biolistic bombardment or the PEG-mediated technique [29].…”

Section: Comparison Among the Production Systems Of Recombinant Prmentioning

confidence: 99%

A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals

Owczarek

Gerszberg

Hnatuszko-Konka

2019

BioMed Research International

113

103

View full text Add to dashboard Cite

Recombinant proteins are produced for various applications in laboratory and industrial settings. Among them, therapeutic applications have evolved into a mature field in recent years, affecting the face of contemporary medical treatment. This, in turn, has stimulated an ever-greater need for innovative technologies for the description, expression, and purification of recombinant protein biopharmaceuticals. Therefore, many biopharmaceuticals are synthesized in heterologous systems to obtain satisfactory yields that cannot be provided by natural sources. As more than 35 years has passed since the first recombinant biopharmaceutical (human insulin) successfully completed clinical trials in humans, we provide a brief review of the available prokaryotic and eukaryotic expression systems, listing the advantages and disadvantages of their use. Some examples of therapeutic proteins expressed in heterologous hosts are also provided. Moreover, technologies for the universal extraction of protein molecules are mentioned here, as is the methodology of their purification.

show abstract

Recombinant proteins in plants

Cited by 12 publications

References 10 publications

Design and Production of Bispecific Antibodies

Design and Production of Bispecific Antibodies

Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases

A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals

Contact Info

Product

Resources

About